GGrantIndex
← Leaderboards

Jonathan D. Licht

Mount Sinai School Of Medicine Of Cuny

$22,549,031
Attributed
$26,463,398
Total exposure
16
Grants
12
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $5M · FY200525
$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$41,356,006 · 18

By mechanism

R01$21,153,136 · 10
U54$13,311,907 · 2
P30$5,921,568 · 3
P01$713,937 · 1
T32$251,458 · 1
R13$4,000 · 1

Top collaborators

Others in their field

Top investigators on “Gene Expression

Research focus

Gene ExpressionGenesCellsMutationPathway InteractionsChromatinMalignant NeoplasmsMediatingGenetic TranscriptionProteinsTumorEpigenetic ProcessMutantAffectCell LineProgramsPreventGeneticMolecularTranscription FactorGene Expression RegulationTumor Suppressor ProteinsSignal TransductionMutate

Grant awards (79)

Histone fold Mutations in Cancer Pathogenesis$705,611
R01 · FY2025 · CA · contact PI
Characterization and targeting of the epigenetic state underlying uveal melanoma liver metastasis$651,147
R01 · FY2025 · CA
Exploring microRNA degradation in T-cell acute lymphoblastic leukemia$503,845
R01 · FY2025 · CA
Defining and targeting epigenetic plasticity-driven drug resistance and immune escape in melanoma$485,968
R01 · FY2025 · CA
University of Florida Health Cancer Center Support Grant$2,134,999
P30 · FY2024 · CA · contact PI
Characterization and targeting of the epigenetic state underlying uveal melanoma liver metastasis$618,592
R01 · FY2024 · CA
Exploring microRNA degradation in T-cell acute lymphoblastic leukemia$478,652
R01 · FY2024 · CA
Defining and targeting epigenetic plasticity-driven drug resistance and immune escape in melanoma$463,483
R01 · FY2024 · CA
Leadership, Planning, and Evaluation$422,844
P30 · FY2024 · CA · contact PI
Histone fold Mutations in Cancer Pathogenesis$335,166
R01 · FY2024 · CA · contact PI
Developmental Funds$305,000
P30 · FY2024 · CA · contact PI
Exploring microRNA degradation in T-cell acute lymphoblastic leukemia$81,624
R01 · FY2024 · CA
Exploring microRNA degradation in T-cell acute lymphoblastic leukemia$26,469
R01 · FY2024 · CA
University of Florida Health Cancer Center Support Grant$2,134,999
P30 · FY2023 · CA · contact PI
Characterization and targeting of the epigenetic state underlying uveal melanoma liver metastasis$638,384
R01 · FY2023 · CA
Exploring microRNA degradation in T-cell acute lymphoblastic leukemia$503,845
R01 · FY2023 · CA
Defining and targeting epigenetic plasticity-driven drug resistance and immune escape in melanoma$478,486
R01 · FY2023 · CA
Leadership, Planning, and Evaluation$422,844
P30 · FY2023 · CA · contact PI
Histone fold Mutations in Cancer Pathogenesis$345,749
R01 · FY2023 · CA · contact PI
Developmental Funds$305,000
P30 · FY2023 · CA · contact PI
UF Health Cancer Center Support Grant - Training Navigator Supplement$195,882
P30 · FY2023 · CA · contact PI
Characterization and targeting of the epigenetic state underlying uveal melanoma liver metastasis$638,640
R01 · FY2022 · CA
Defining and targeting epigenetic plasticity-driven drug resistance and immune escape in melanoma$498,307
R01 · FY2022 · CA
Histone fold Mutations in Cancer Pathogenesis$352,805
R01 · FY2022 · CA · contact PI
Characterization and targeting of the epigenetic state underlying uveal melanoma liver metastasis$684,278
R01 · FY2021 · CA
Spatio-Temporal Organization of Chromatin and Information Transfer in Cancer$500,000
U54 · FY2020 · CA
The Role of MMSET in the Pathogenesis and Progression of Lymphoid Malignancy$390,734
R01 · FY2020 · CA · contact PI
KDM6A mutation as an epigenetic driver of multiple myeloma$56,953
R01 · FY2020 · CA · contact PI
Spatio-Temporal Organization of Chromatin and Information Transfer in Cancer$2,004,909
U54 · FY2019 · CA
Project 2: Molecular Modulation of Chromatin and Nuclear Structure in Cancer$582,074
U54 · FY2019 · CA · contact PI
The Role of MMSET in the Pathogenesis and Progression of Lymphoid Malignancy$338,378
R01 · FY2019 · CA · contact PI
UTX, MLL AND PATHOGENIC DEREGULATION OF HISTONE METHYLATION IN MULTIPLE MYELOMA$336,968
R01 · FY2019 · CA · contact PI
2019 Cancer Genetics and Epigenetics GRC/GRS$4,000
R13 · FY2019 · CA · contact PI
Spatio-Temporal Organization of Chromatin and Information Transfer in Cancer$2,095,133
U54 · FY2018 · CA
Project 2: Molecular Modulation of Chromatin and Nuclear Structure in Cancer$677,567
U54 · FY2018 · CA · contact PI
The Role of MMSET in the Pathogenesis and Progression of Lymphoid Malignancy$348,844
R01 · FY2018 · CA · contact PI
UTX, MLL AND PATHOGENIC DEREGULATION OF HISTONE METHYLATION IN MULTIPLE MYELOMA$347,390
R01 · FY2018 · CA · contact PI
Spatio-Temporal Organization of Chromatin and Information Transfer in Cancer$1,762,723
U54 · FY2017 · CA
Project 2: Molecular Modulation of Chromatin and Nuclear Structure in Cancer$562,587
U54 · FY2017 · CA · contact PI
The Role of MMSET in the Pathogenesis and Progression of Lymphoid Malignancy$348,844
R01 · FY2017 · CA · contact PI
UTX, MLL AND PATHOGENIC DEREGULATION OF HISTONE METHYLATION IN MULTIPLE MYELOMA$347,390
R01 · FY2017 · CA · contact PI
Spatio-Temporal Organization of Chromatin and Information Transfer in Cancer$2,074,472
U54 · FY2016 · CA
Project 2: Molecular Modulation of Chromatin and Nuclear Structure in Cancer$542,300
U54 · FY2016 · CA · contact PI
The Role of MMSET in the Pathogenesis and Progression of Lymphoid Malignancy$348,844
R01 · FY2016 · CA · contact PI
Spatio-Temporal Organization of Chromatin and Information Transfer in Cancer$1,989,491
U54 · FY2015 · CA
Project 2: Molecular Modulation of Chromatin and Nuclear Structure in Cancer$520,651
U54 · FY2015 · CA · contact PI
UTX, MLL AND PATHOGENIC DEREGULATION OF HISTONE METHYLATION IN MULTIPLE MYELOMA$307,622
R01 · FY2015 · CA · contact PI
UTX, MLL and Pathogenic Deregulation of Histone Methylation in Multiple Myeloma$51,435
R01 · FY2015 · CA · contact PI
UTX, MLL and Pathogenic Deregulation of Histone Methylation in Multiple Myeloma$373,041
R01 · FY2014 · CA · contact PI
Transcriptional Functions and Targets of the MMSET Protein of t(4:14) Myeloma$288,529
R01 · FY2013 · CA · contact PI
Clinical Oncology Research Training Program$251,458
T32 · FY2013 · CA · contact PI
Transcriptional Functions and Targets of the MMSET Protein of t(4:14) Myeloma$306,945
R01 · FY2012 · CA · contact PI
Transcriptional Functions and Targets of the MMSET Protein of t(4:14) Myeloma$306,945
R01 · FY2011 · CA · contact PI
Transcriptional Functions and Targets of the MMSET Protein of t(4:14) Myeloma$316,438
R01 · FY2010 · CA · contact PI
SPROUTY, A WT1 TARGET FOR GROWTH AND DEVELOPMENT$273,189
R01 · FY2010 · CA · contact PI
Transcriptional Functions and Targets of the MMSET Protein of t(4:14) Myeloma$316,438
R01 · FY2009 · CA · contact PI
SPROUTY, A WT1 TARGET FOR GROWTH AND DEVELOPMENT$273,189
R01 · FY2009 · CA · contact PI
The Molecular Pathology of Myeloproliferative Disease$530,122
R01 · FY2008 · HL · contact PI
SPROUTY, A WT1 TARGET FOR GROWTH AND DEVELOPMENT$273,189
R01 · FY2008 · CA · contact PI
The Molecular Pathology of Myeloproliferative Disease$540,938
R01 · FY2007 · HL · contact PI
The PLZF Protein of t(11;17)-Promyelocytic Leukemia$382,145
R01 · FY2007 · CA · contact PI
SPROUTY, A WT1 TARGET FOR GROWTH AND DEVELOPMENT$273,189
R01 · FY2007 · CA · contact PI
The Molecular Pathology of Myeloproliferative Disease$588,707
R01 · FY2006 · HL · contact PI
The PLZF Protein of t(11;17)-Promyelocytic Leukemia$390,382
R01 · FY2006 · CA · contact PI
SPROUTY, A WT1 TARGET FOR GROWTH AND DEVELOPMENT$315,817
R01 · FY2006 · CA · contact PI
The Molecular Pathology of Myeloproliferative Disease$1
R01 · FY2006 · HL · contact PI
The Molecular Pathology of Myeloproliferative Disease$620,250
R01 · FY2005 · HL
The PLZF Protein of t(11;17)-Promyelocytic Leukemia$390,258
R01 · FY2005 · CA
SPROUTY, A WT1 TARGET FOR GROWTH AND DEVELOPMENT$322,262
R01 · FY2005 · CA
The PLZF Protein of t(11;17)-Promyelocytic Leukemia$379,845
R01 · FY2004 · CA
SPROUTY, A WT1 TARGET FOR GROWTH AND DEVELOPMENT$322,262
R01 · FY2004 · CA
The PLZF Protein of t(11;17)-Promyelocytic Leukemia$403,531
R01 · FY2003 · CA
SPROUTY, A WT1 TARGET FOR GROWTH AND DEVELOPMENT$322,262
R01 · FY2003 · CA
SPROUTY, A WT1 TARGET FOR GROWTH AND DEVELOPMENT$322,262
R01 · FY2002 · CA
Convergent functions of p53 and BRCA1 in gene regulation$237,979
P01 · FY2002 · CA
SPROUTY, A WT1 TARGET FOR GROWTH AND DEVELOPMENT$322,262
R01 · FY2001 · CA
Convergent functions of p53 and BRCA1 in gene regulation$237,979
P01 · FY2001 · CA
TRANSCRIPTIONAL REPRESSION BY THE WTI PROTEIN$284,285
R01 · FY2000 · CA
Convergent functions of p53 and BRCA1 in gene regulation$237,979
P01 · FY2000 · CA